Patheon has signed a slew of agreements to boost its portfolio of contract drug development and manufacturing services, forging new alliances with Omnicare, Depomed, Senopsys and Solvias.
Clinical trial materials
The Canadian firm has signed a master service agreement with Omnicare Clinical Research, a leading global CRO, for distribution of clinical trial materials in Europe and Asia Pacific.
Omnicare Clinical Research’s clinical supplies division will provide Patheon’s customers with various clinical supply services, including monitoring, distribution and return accountability, said Patheon. The Canadian firm said it would now be able to provide a “greater variety of manufacturing and packaging options, including distribution locations for clinical trial materials in Europe and Asia Pacific.”
In the area of drug delivery, Patheon has re-launched its alliance with Depomed, a US company best known for its polymer-based AcuForm technology which improves the bioavailability of medicines by holding active ingredients in the gastrointestinal tract.
Patheon will make AcuForm available through its global network of manufacturing and distribution facilities, promoting it alongside its solid, semi-solid, sterile and liquid dosage forms as part of its Commercial Manufacturing division.
AcuForm gastric retention tablets stay in the stomach for eight to nine hours with food and slowly release the drug, providing controlled once-a-day dosing.
Meanwhile, Patheon forged an agreement with Senopsys to develop dose formulations with enhanced palatability, particularly for children.
The alliance between the two companies will allow Patheon to offer services related to the development of products with enhanced sensory characteristics such as smell, taste, texture, mouthfeel and appearance.
Senopsys said it would “provide Patheon with expertise in human taste panel assessment and sensory-directed taste optimisation while we can utilise Patheon’s global network of sites to develop customer drug products.”
Just ahead of the Senopsys deal, Patheon also announced it had entered into a global alliance with Switzerland’s Solvias AG in the area of drug development.
The deal will bring together Patheon’s formulation development expertise with Solvias’ capabilities in pre-formulation and solid state chemistry.
The two companies will offer a range of services including API characterisation, salt selection and co-crystallisation, polymorphism screening, solubility determination, excipient compatibility and formulation.